RXRX Hedge Fund Ownership (Q2 2026)

Recursion Pharmaceuticals In (RXRX)

336 + Investors. Track Smart Money conviction in RXRX. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — RXRX

Based on 344 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added RXRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

344 hedge funds hold RXRX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

📶

Steady growth — +4% more funds vs a year ago

fund count last 6Q

+13 new funds entered over the past year (+4% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.

🟡

Slight buying edge — 56% buying

190 buying152 selling

Last quarter: 190 funds bought or added vs 152 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

➡️

Steady new buyers — ~55 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 47 → 69 → 60 → 55. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

🔒

47% of holders stayed for 2+ years

■ 47% conviction (2yr+) ■ 27% medium ■ 25% new

163 out of 344 hedge funds have held RXRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💰

Value +80% but shares only +8% — price-driven

Value

+80%

+7%

Last quarter: the total dollar value of institutional holdings rose +80%, but actual share count only changed +8%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

➡️

Steady discovery — ~55 new funds/quarter

58 → 47 → 69 → 60 → 55 new funds/Q

New funds entering each quarter: 47 → 69 → 60 → 55. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🏛️

Veteran-anchored — 49% veterans vs 28% newcomers

■ 49% veterans ■ 23% 1-2yr ■ 28% new

Entry-cohort mix of 355 holders: 174 (49%) are 2+ year veterans, 83 entered 1–2 years ago, and 98 (28%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 61% AUM from top-100 funds

61% from top-100 AUM funds

56 of 339 holders are among the 100 largest funds by AUM, controlling 61% of total institutional value in RXRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

3.7

out of 10

Low Exit Risk

Exit risk score 3.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	336	339	-0.88%
13F Shares	370M	346M	6.92%
Total Value	$1.35B	$1.06B	27.22%
New Positions	54	60	-6
Increased Positions	129	131	-2
Closed Positions	52	51	+1
Reduced Positions	98	86	+12
Total Calls	11	12	-8.33%
Total Puts	5	5	-
PUT/CALL Ratio	0.45	0.42	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

336

339

-0.88%

13F Shares

370M

346M

6.92%

Total Value

$1.35B

$1.06B

27.22%

New Positions

-6

Increased Positions

129

131

-2

Closed Positions

Reduced Positions

+12

Total Calls

-8.33%

Total Puts

PUT/CALL Ratio

0.45

0.42

Bullish

Institutional Holders (2026 Q2)

336 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in RXRX. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 RXRX holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	DCVC Opportunity Fund II GP, LLC	84.30%	3,951,141	$14.5M
2	Data Collective IV GP, LLC	27.76%	5,941,120	$21.8M
3	MIC Capital Management UK LLP	8.98%	9,644,033	$35.4M
4	Nan Fung Group Holdings Ltd	1.66%	595,287	$2.2M
5	ARK Investment Management LLC	0.98%	41,337,632	$151.7M
6	Carroll Investors, Inc	0.78%	500,349	$1.8M
7	Pivotal bioVenture Partners Investment Advisor LLC	0.71%	595,518	$2.2M
8	IQ EQ FUND MANAGEMENT (IRELAND) Ltd	0.61%	2,604,317	$9.6M
9	Green Alpha Advisors, LLC	0.36%	147,544	$541K
10	Soviero Asset Management, LP	0.31%	200,000	$734K
11	Softbank Group CORP.	0.28%	13,636,515	$50.0M
12	Amova Asset Management Americas, Inc.	0.26%	5,511,687	$20.2M
13	Lingotto Investment Management LLP	0.17%	2,206,661	$8.1M
14	Themes Management Co LLC	0.17%	69,782	$256K
15	Headlands Technologies LLC	0.15%	387,749	$1.4M
16	Comprehensive Financial Management LLC	0.11%	941,895	$3.5M
17	Allen Operations LLC	0.11%	217,657	$799K
18	Kieckhefer Group LLC	0.11%	74,000	$272K
19	Cherry Creek Investment Advisors, Inc.	0.09%	64,998	$239K
20	Virtus Investment Advisers, LLC	0.09%	103,872	$381K
21	Baillie Gifford & Co	0.08%	23,487,907	$86.2M
22	MQS Management LLC	0.07%	16,127	$59K
23	180 Wealth Advisors, LLC	0.07%	190,562	$699K
24	Pier 88 Investment Partners LLC	0.06%	69,200	$254K
25	VARCOV Co.	0.06%	42,837	$157K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Recursion Pharmaceuticals In (RXRX)

What does the Smart Money Trend signal show for RXRX?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added RXRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for RXRX?

Slight buying edge — 56% buying: Last quarter: 190 funds bought or added vs 152 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for RXRX holders?

Elite ownership — 61% AUM from top-100 funds: 56 of 339 holders are among the 100 largest funds by AUM, controlling 61% of total institutional value in RXRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held RXRX?

47% of holders stayed for 2+ years: 163 out of 344 hedge funds have held RXRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Recursion Pharmaceuticals In (RXRX)

Smart Money Signals — RXRX

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Steady growth — +4% more funds vs a year ago

Slight buying edge — 56% buying

Steady new buyers — ~55 new funds per quarter

47% of holders stayed for 2+ years

Value +80% but shares only +8% — price-driven

Steady discovery — ~55 new funds/quarter

Veteran-anchored — 49% veterans vs 28% newcomers

Elite ownership — 61% AUM from top-100 funds

Institutional Sentiment Summary — RXRX

Hedge Fund Ownership: RXRX

Market Analysis: RXRX

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: RXRX

Hedge Fund Positioning: RXRX

Statistics: RXRX

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Recursion Pharmaceuticals In (RXRX)

Welcome to 13Foresight!